Em recrutamento
FASE
Número Europeu 2025-524109-33-00
SATROPIN
Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/​HER2- Breast Cancer (SATROPIN)
Detalhes
Destaques